# ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

> **NCT03107663** · PHASE1 · COMPLETED · sponsor: **ImaginAb, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Positron-Emission Tomography
- Immunomodulation
- Metastatic Solid Malignancies
- Hodgkin Lymphoma

## Interventions

- **DRUG:** ⁸⁹Zr-Df-IAB22M2C Infusion

## Key facts

- **NCT ID:** NCT03107663
- **Lead sponsor:** ImaginAb, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-19
- **Primary completion:** 2018-08-16
- **Final completion:** 2018-08-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03107663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03107663, "⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03107663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*